Pharmaceuticals, Biotechnology and Life Sciences
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
HAUPPAUGE, N.Y.–(BUSINESS WIRE)–The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39th Annual…
24-Month Average IOP Reductions of 7.9 mmHg and 7.4 mmHg in Fast- and Slow-Release iDose TR Arms, Respectively Favorable Safety…
24-Month Average IOP Reductions of 7.9 mmHg and 7.4 mmHg in Fast- and Slow-Release iDose TR Arms, Respectively Favorable Safety…
HAUPPAUGE, N.Y.–(BUSINESS WIRE)–The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39th Annual…
– Collaboration includes two T-cell programs and an expansive discovery program to identify natural killer (NK) cell targets – Potential…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
Initial program to focus on development of a companion diagnostic for HiberCell’s novel immunotherapy, Imprime PGG, to aid in patient…
Substantial IOP Reduction Observed with Highly Favorable Safety Profile Through 12 Months 76% of Subjects Achieved 20% or Greater Reduction…
Substantial IOP Reduction Observed with Highly Favorable Safety Profile Through 12 Months 76% of Subjects Achieved 20% or Greater Reduction…